Investment analysts at Leerink Swann initiated coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) in a research note issued on Monday, The Fly reports. The brokerage set an “outperform” rating on the stock.
Several other equities analysts also recently commented on CRNX. Piper Jaffray Companies started coverage on shares of Crinetics Pharmaceuticals in a research note on Monday. They set an “overweight” rating for the company. JPMorgan Chase & Co. started coverage on shares of Crinetics Pharmaceuticals in a research note on Monday. They set a “neutral” rating for the company.
Shares of Crinetics Pharmaceuticals opened at $30.68 on Monday, MarketBeat.com reports. Crinetics Pharmaceuticals has a 12 month low of $19.23 and a 12 month high of $32.79.
About Crinetics Pharmaceuticals
There is no company description available for Crinetics Pharmaceuticals Inc
Read More: Should you buy a closed-end mutual fund?
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.